Full Press Release Details
CytoSorbents to Host International Webinar on
the Worldwide Experience Using CytoSorb in Critically Ill Patients with COVID-19
Upcoming international webinar on September
16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients
MONMOUTH JUNCTION, N.J., September 14, 2021 - CytoSorbents
Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces
an upcoming live webinar to provide a global perspective on CytoSorb
blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT / 5:00 p.m. CET. The webinar will highlight
a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically
ill COVID-19 patients worldwide, including the recently announced topline results from the U.S.
multicenter CTC Registry using CytoSorb with ECMO under U.S. FDA Emergency Use Authorization.
Live Webinar details:
Therapy in COVID-19 Patients
International Experts Meeting in Intensive Care Series
Eastern / 5:00 p.m. CET
results from the U.S. CTC multicenter registry
about current studies and experiences
inflammatory syndrome
The session will conclude
with a live, moderated Question and Answer session.
Highlighted data to be presented are expected
Dr. Joerg Scheier, Vice President of Medical and
Clinical Affairs of CytoSorbents, stated, "We are excited to see that the expanding numbers of positive clinical experiences with
CytoSorb in COVID-19 patients are now being reflected by an increasing number of scientific peer review publications from many different
geographies. We believe the ability to reduce inflammatory mediators in these patients is a key reason that common clinical benefits are
being reported in COVID-19 patients treated with CytoSorb. Finally, clinicians routinely comment that CytoSorb is easy to use, irrespective
of whether the device is set up within a renal replacement, an extracorporeal membrane oxygenation (ECMO), or a standalone circuit in
hemoperfusion mode. This has given physicians greater flexibility in how and when they treat patients with CytoSorb."
Overall, CytoSorb has been used in more than 6,500
critically ill COVID-19 patients in more than 30 countries worldwide to reduce cytokine storm and other circulating inflammatory mediators
with the goals of reducing severe systemic hyper-inflammation and damage to vital organs like the lungs, heart, and kidneys, while improving
the chances of survival.
About CytoSorbents Corporation (NASDAQ: CTSO)
Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.
Its flagship product, CytoSorb , is approved in the European Union
with distribution in 68 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm"
or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and
patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb
is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications,
including multiple organ failure. More than 143,000 CytoSorb devices have been delivered to date. CytoSorb was originally
introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were
received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor
and rivaroxaban during cardiothoracic surgery. CytoSorb has also
received FDA Emergency Use Authorization in the United States for use
in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb-ATR Antithrombotic Removal
System, which is based on the same polymer technology as CytoSorb, has also been granted FDA
Breakthrough Designation for the removal of ticagrelor, as well as FDA
Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs rivaroxaban and apixaban in a cardiopulmonary
bypass circuit during urgent cardiothoracic surgery.
CytoSorb has been granted U.S. FDA Emergency Use
Authorization in the COVID-19 pandemic as an extracorporeal cytokine adsorber for use in adult, critically ill COVID-19 patients with
imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients
with COVID-19 infection. The CytoSorb device is authorized only for the duration of the declaration that circumstances exist justifying
the authorization of the emergency use of the CytoSorb device under Section 564(b)(l) of the Act, 21 U.S.C 360bbb-3(b)(1), unless
the authorization is terminated or revoked sooner.
CytoSorbents' purification technologies
are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5
million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart,
Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command
(USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification
technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending,
including ECOS-300CY , CytoSorb-XL , HemoDefend-RBC , HemoDefend-BGA , VetResQ , K+ontrol ,
DrugSorb , DrugSorb-ATR , ContrastSorb, and others. For more information, please visit the Company's websites
Forward-Looking Statements
This press release includes forward-looking statements
intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements about our plans, objectives, anticipated future results and performance, representations
and contentions and are not historical facts and typically are identified by use of terms such as "may," "should,"
"could," "expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some forward-looking statements are expressed differently. You
should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but
our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 9, 2021, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications
to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our
business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required
under the Federal securities laws.
Investor Relations Contact:
Vice President, Investor Relations
and Corporate Communications